GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Syneos Health Inc (FRA:8IN) » Definitions » EV-to-EBITDA

Syneos Health (FRA:8IN) EV-to-EBITDA : 16.12 (As of May. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Syneos Health EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Syneos Health's enterprise value is €6,884 Mil. Syneos Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €427 Mil. Therefore, Syneos Health's EV-to-EBITDA for today is 16.12.

The historical rank and industry rank for Syneos Health's EV-to-EBITDA or its related term are showing as below:

FRA:8IN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.99   Med: 17.67   Max: 70.6
Current: 16.12

During the past 12 years, the highest EV-to-EBITDA of Syneos Health was 70.60. The lowest was 8.99. And the median was 17.67.

FRA:8IN's EV-to-EBITDA is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 16.29 vs FRA:8IN: 16.12

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Syneos Health's stock price is €40.00. Syneos Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €0.713. Therefore, Syneos Health's PE Ratio for today is 56.10.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Syneos Health EV-to-EBITDA Historical Data

The historical data trend for Syneos Health's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneos Health EV-to-EBITDA Chart

Syneos Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.29 18.48 18.89 21.37 10.10

Syneos Health Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.83 11.84 10.10 11.77 15.45

Competitive Comparison of Syneos Health's EV-to-EBITDA

For the Diagnostics & Research subindustry, Syneos Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syneos Health's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Syneos Health's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Syneos Health's EV-to-EBITDA falls into.



Syneos Health EV-to-EBITDA Calculation

Syneos Health's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6883.958/427.109
=16.12

Syneos Health's current Enterprise Value is €6,884 Mil.
Syneos Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €427 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syneos Health  (FRA:8IN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Syneos Health's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=40.00/0.713
=56.10

Syneos Health's share price for today is €40.00.
Syneos Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.713.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Syneos Health EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Syneos Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Syneos Health (FRA:8IN) Business Description

Traded in Other Exchanges
N/A
Address
1030 Sync Street, Morrisville, NC, USA, 27560-5468
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Syneos Health (FRA:8IN) Headlines

No Headlines